国产99精品,国产精品v,99热精品国产三级在线观看,免费精品,国产精品一区在线观看,精品国产第一页,国产精品一区在线观看

首頁(yè) /科研細(xì)胞 /人源細(xì)胞系 /其他人源細(xì)胞系 /22Rv1(人前列腺癌細(xì)胞)

22Rv1(人前列腺癌細(xì)胞)

CBP60341

產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
I. General information 
Synonyms: 22Rv1
Background: 22Rv1 is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft.
Species: Homo sapiens, human
Tissue: prostate
Disease: carcinoma
Morphology: epithelial
Growth Mode: adherent
Doubling Time: 40 hours
DNA Profile: Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 9,12
D16S539: 12
D5S818: 11,12,13
D7S820: 9,10,11
THO1: 6,9.3
TPOX: 8
vWA: 15,21
Our Cell Line Authentication Service
Culture Medium:

RPMI-1640+10%FBS

22Rv1完全培養(yǎng)基,# CBP60341M
We strongly suggest to purchase the complete medium from us.

Cryopreservation medium: 90%FBS+10%DMSO
Antigen Expression: prostate specific antigen (PSA)
Receptor Expression: androgen receptor
Tumor Formation: Yes, forms tumors in nude mice
Comments: The cell line expresses prostate specific antigen (PSA). Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis.
Growth is stimulated by epidermal growth factor (EGF) but is not inhibited by transforming growth factor beta-1 (TGF beta- 1).
Recently , it has been shown that 22Rv1 prostate carcinoma cells produce high-titer of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus).
For more information, please contact us(4008-750-250).

客服

微信

掃一掃,添加二維碼

電話

留言

藥靶模型聯(lián)系方式: 華東銷(xiāo)售經(jīng)理:18240630236/15715191010 華中&華西銷(xiāo)售經(jīng)理:18071545918 華中&西南銷(xiāo)售經(jīng)理:13871580511 華北銷(xiāo)售經(jīng)理:18628311252 全國(guó)銷(xiāo)售經(jīng)理:13816461235
診斷標(biāo)準(zhǔn)品聯(lián)系方式: 華東銷(xiāo)售經(jīng)理:15000320447 華北銷(xiāo)售經(jīng)理:18628311252 華中&華西銷(xiāo)售經(jīng)理:18071545918 華中&西南銷(xiāo)售經(jīng)理:13871580511 全國(guó)銷(xiāo)售經(jīng)理:13816461235

掃二維碼

立即提交